ArticleInternational journal of cardiology. Heart & vasculature2025
Lipoprotein(a) and the risk of type I cardiorenal syndrome in patients with coronary artery disease: A retrospective clinical study.
Article in International journal of cardiology. Heart & vasculature, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Integrating genomic insights and artificial intelligence to elucidate lipoprotein(a)-mediated risk in cardio-renal syndrome.Annals of medicine and surgery (2012) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The present study aimed to investigate the correlation between lipoprotein(a) (Lp-a) and coronary artery disease (CAD) complicated by type I cardiorenal syndrome (CRS). Methods: We conducted a retrospective analysis of patients diagnosed with CAD admitted to the Department of Cardiovascular Medicine at Shaoxing Central Hospital from January 2021 to December 2022, with chief complaints of "chest distress and dyspnea." Patient demographic data, biochemical indicators (including blood lipid levels and serum creatinine), cardiac function markers (such as pro-brain natriuretic peptide, pro-BNP), echocardiography, and coronary angiography results were collected. Patients were categorized into two groups based on estimated glomerular filtration rate (e-GFR): the CRS group (e-GFR < 60 mL/min/1.73 m Results: A total of 269 patients were included, comprising 149 males and 120 females with an average age of 76.0 ± 11.4 years. Significant differences were observed between the CRS and SHF groups in terms of age, history of hypertension, diabetes, myocardial infarction, serum triglycerides, Lp-a, and creatinine (all P < 0.05). Spearman's correlation analysis revealed an inverse relationship between Lp-a and e-GFR (r = -0.588, P < 0.05). Multivariable logistic regression analysis indicated that Lp-a (OR = 1.980, 95 % CI: 1.269-2.992, P = 0.027) and age (OR = 1.584, 95 % CI: 0.955-1.913, P = 0.006) were positively associated with the development of CRS. Conclusion: Serum Lp-a levels are positively correlated with the occurrence of CRS, potentially serving as an independent risk factor for CRS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.